KFDA approves Micardis for hypertension

The Korea Food and Drug Administration said on January 22 that it has approved the supplemental indication of Micardis (telmisartan), an angiotensin II receptor blocker (ARB), for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensi...